Avalo Therapeutics Files 8-K

Ticker: AVTX · Form: 8-K · Filed: May 8, 2025 · CIK: 1534120

Avalo Therapeutics, INC. 8-K Filing Summary
FieldDetail
CompanyAvalo Therapeutics, INC. (AVTX)
Form Type8-K
Filed DateMay 8, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: regulatory-filing, 8-K

Related Tickers: AVLO

TL;DR

AVLO filed an 8-K on 5/8/25. Standard reporting, check exhibits for details.

AI Summary

Avalo Therapeutics, Inc. filed an 8-K on May 8, 2025, reporting "Other Events" and "Financial Statements and Exhibits." The company, formerly known as Cerecor Inc., is incorporated in Delaware and headquartered in Wayne, PA. This filing does not appear to contain specific financial transactions or material events beyond routine reporting.

Why It Matters

This 8-K filing indicates Avalo Therapeutics is meeting its regulatory reporting obligations. Investors should review the exhibits for any specific updates or disclosures.

Risk Assessment

Risk Level: low — The filing appears to be routine and does not disclose any new material events, significant financial changes, or strategic shifts.

Key Players & Entities

FAQ

What is the primary purpose of this 8-K filing for Avalo Therapeutics?

This 8-K filing serves to report "Other Events" and "Financial Statements and Exhibits" as of May 8, 2025, fulfilling Avalo Therapeutics' regulatory reporting obligations.

What was Avalo Therapeutics' former name?

Avalo Therapeutics, Inc. was formerly known as Cerecor Inc.

In which state is Avalo Therapeutics incorporated?

Avalo Therapeutics, Inc. is incorporated in Delaware.

Where are Avalo Therapeutics' principal executive offices located?

Avalo Therapeutics, Inc.'s principal executive offices are located at 540 Gaither Road, Suite 400, Rockville, Maryland 20850.

What is the filing date for this 8-K report?

The filing date for this 8-K report is May 8, 2025.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on May 8, 2025 regarding Avalo Therapeutics, Inc. (AVTX).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing